Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oregon Health & Science University

www.ohsu.edu/tech-transfer

Latest From Oregon Health & Science University

In Vivo's Deals Of The Month, October 2017

In Vivo's editors pick October's most significant deals, including bold moves from Vir Biotechnology and the birth of a major generics player. (Free article.)

Deals BioPharmaceutical

$500m And Counting: Vir Puts Big Money To Work In Infectious Diseases

Vir Biotechnology launched in January with $150m and a focus on infectious diseases. Now, the George Scangos-led venture has raised more than $500m and signed multiple collaboration agreements, including deals with Alnylam and Visterra worth as much as $1bn each.

Financing Deals

Venture Funding Deals: Complexa Raises $62m; Evelo, Kezar Bring In $50m Each

Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.

Deals Financing

Venture Funding Deals: Takeda Ups Its Bet On Immuno-Oncology Play Maverick

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.

StartUps and SMEs Financing
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register